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A B ST R AC T 
 
A R T IC LE D A T A 
According to statistical data published in 2019, breast cancer is among the 
leading causes of death in women worldwide. The serine/threonine kinase 
(AKT) or protein kinase B (PkB) signaling pathway is activated by 
phosphorylation processes, which further is associated with cell growth, 
proliferation, and survival, but also with activation of glucose metabolism. 
Mutations of the AKT signaling pathway components (especially PI3KCA 
and PTEN) have been observed in breast cancer patients, which are 
associated with resistance to hormonal treatment. Many clinical trials are 
testing the effect of AKT inhibition in order to block the growth and 
proliferation of breast cancer cells. The purpose of this review is to present 
the incidence of this neoplastic disease, to describe AKT signaling 
pathways activation, mutations that occur at its level, and inhibitors that 
can block this protein kinase. 
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Introduction  
Following a systemic analysis conducted over a period 
of 27 years (1990-2017) regarding the incidence of 
cancer, published online in September 2019, there were 
24.5 million cases and 9.6 million deaths registered 
worldwide [1]. Skin, breast, and colorectal cancer were 
the most common neoplastic disorders reported among 
women, representing 54% of all cancers [1]. In the Global 
top 10 cancers, breast cancer was the third most common 
cancer overall, with 2 million incident cases registered in 
2017. Of the 143 countries that participated in the 
systemic analysis, in 112 countries breast cancer was the 
most common cause of death among women [1]. 
According to statistical data from Romania, the 
incidence of neoplastic diseases in 2018 registered at 
83,461 cases for both sexes, with 50,902 deaths [2]. In 
Romanian women, the 5 most common types of cancer are 
breast, colorectal, cervix uteri, lung, and corpus uteri. In 
2018, 38,439 cases of cancer were diagnosed in women, of 
which 9625 were breast cancer [2]. Last year, Romania 
registered 30,100 deaths among men and 20,200 among 
women. In the case of women of Romanian origin, as well 
as in other countries, breast cancer represents the most 
common neoplastic disease, with 8,981 cases reported.  
Breast palpation and clinical breast examination are 
the classic methods available to all women for detecting 
tumors, as mammography is not generally available at the 
public health care level in many areas [3]. 
Discussions 
Breast cancer subtypes  
Currently, for a more accurate diagnosis of breast 
cancer, a number of factors have been proposed, such as 
tumor size and degree, histological subtype, 
lymphovascular invasion of tumor cells, presence of 
tumor cell receptors, and axial lymph nodes.  
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Ki-67 is currently used as a valuable parameter that 
expresses the potential for proliferation and division of 
tumor cells. By combining genetic tests with histological 
analyses (macroscopic and microscopic) and 
immunohistochemistry, it is possible to detect the presence 
of cell surface receptors [estrogen, progesterone, and 
human epidermal growth factor receptor 2 (HER2)] [4].  
Luminal A, Luminal B with HER 2 negative, Luminal 
B with Her 2 positive, HER 2 enriched, and basal-like 
(triple negative) are the most recent classifications (in 
2013) for breast cancer, according to the St Gallen 
classification system (Table 1) [4]. 
Table 1. According to St. Gallen classification [adapted 
from 4-7] 
Breast 
cancer 
subtypes 
ER / Pr HER 2 Ki67 Mutated genes Treatment 
Luminal A +and or/- - <14% PIK3CA(45%) 
AKT1(4%) 
PTEN(4%) 
Endocrine 
therapy 
Luminal B 
and HER 
negative 
+ and 
or/- 
- ≥14% PIK3CA (29%) Endocrine 
therapy± 
chemotherapy 
Luminal B 
and HER 
positive 
+ and 
or/- 
+ Any 
ki-67 
PIK3CA (29%) Chemotherapy
+ anti+HER2 
therapy+endoc
rine therapy 
HER-2-
enriched 
-/- + Any 
ki-67 
PIK3CA (39%) Chemotherapy 
+ anti+HER 2 
Basal-like 
(triple 
negative) 
-/- - - PIK3CA (7%) Chemotherapy 
Pi3k signaling pathway  
Phosphatidylinositol-3 kinases (PI3K) are a family of 
lipid structure kinases involved in the regulation of 
numerous biological processes, such as cell proliferation, 
survival and differentiation, metabolism, and migration 
[8]. Depending on their structure and kinetic differences, 
these protein kinases can be divided into 3 classes: class I, 
II, and III. PI3Kα, PI3Kβ, PI3KŸ and PI3Kچ belong to 
class I and are unfortunately abnormally activated in 
breast cancer [9]. These kinases contain a regulatory 
subunit and a catalytic subunit, so for class IA, there are 3 
catalytic subunits (p110α, p110β, p110چ) that are encoded 
by PIK3CA, PIK3CB, PIK3CD. The regulatory subunits 
of class IA, p85α, p85β and p55Ÿ, are encoded by 
PIK3R1, PIKR2 and PIKR3 [8, 9]. In the case of IB class 
of protein kinases, which are heterodimers, the catalytic 
subunit p110Ÿ is encoded by PIK3CG, presenting one or 
two regulatory subunits, namely p101 encoded by 
PIK3CR5 or p87 encoded by PIK3R6 [10]. All cell types 
express the catalytic subunits p110α and p110β, while 
p110Ÿ and p110چ are expressed only by leukocytes [10]. 
Class I PI3Ks are recruited to the plasma membrane 
when the activator binds to the specific receptor, so the 
catalytic subunit phosphorylates phosphatidylinositol 4,5 
bisphosphate (PIP2) to phosphatidyl inositol 3,4,5 
triphosphate (PIP3). PIP3 acts as a secondary messenger 
and coordinates AKT localization at the plasma membrane 
and then phosphorylation by PDK1 (phosphoinositide 
dependent protein kinase-1) [10]. PDK1 phosphorylates 
AKT at threonine residue 308, and for complete activation, 
serine residue 473 is phosphorylated by mTOR 
(mammalian target of rapamycin) [10,11]. 
mTOR is a serine / threonine protein kinase complex 
that is composed of mTORC 1 and mTORC 2, these 
having similar structure but different functions. mTORC2 
phosphorylates AKT for full activation at serine. 
Following activation by phosphorylation of AKT, this 
protein kinase phosphorylates and thus inhibits tuberous 
sclerosis complex 1 and 2 (TSC 1 and 2), this inhibition 
leading to the activation of mTORC1. Once activated 
mTORC1, it activates in turn 40 S ribosomal protein S6 
kinase (S6K) and eukaryotic initiation factor 4E binding 
protein (4EBP1) which lead to cell growth and activation 
of glucose metabolism [12,13]. 
Phosphatase and tensin homolog (PTEN) negatively 
regulate AKT by dephosphorylating PIP3 to PIP2. Apart 
from PTEN, it has recently been observed that there may 
be another negative regulator for PIP3, polyphosphate 4-
phosphatase type II (INPP4B) [14]. 
AKT activation in cancer  
The incidence of mutations that occur in the AKT 
signaling pathway in breast cancer is 25%. Most of these 
mutations are found in the PIKCA that encodes the p110α 
catalytic subunit, with the substitution of a single amino 
acid such as E545K and E542K in the helical domain 
(exon 9) and H1047R in the kinase domain (exon20) [15]. 
Mutations occurring both in the helical and kinase 
domains will increase the enzymatic activity, of components 
of AKT signaling pathways, which will promote oncogenic 
transformation. Depending on the breast cancer subtype, 
AKT mutations occur around 20-25% [16]. 
An increase of the mutations of over 30% is registered in 
the case of the tumor that has hormonal receptors, for 
HER2+, is registered 25% AKT mutations. In contrast, triple 
negative breast cancer has the lowest rate of AKT mutations 
[16]. A number of somatic gene mutations have already been 
observed within this signaling pathway, including PI3CA, 
PIKR1, PTEN, AKT1, which will result in either increased 
PI3K activity or loss of PTEN functionality [16]. 
In mammals, class 1 protein kinases are divided into 
1A and 1B, the first class being activated by tyrosine 
kinase receptor (RTKs), and the second class by receptors 
coupled with G proteins. 
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The involvement of PI3K/ AKT signaling pathways in 
breast cancer pathogenesis can be achieved through 
several mechanisms: 
1. The occurrence of mutations or amplification of 
PI3KCA, PIK3CB, PIK3R1 leads to increased 
activity of AKT signaling pathways. 
2. Overexpression of some target molecules or 
activating signals such as HER 2, epidermal growth 
factor receptor (EGFR) , insulin-like growth factor 
receptor 1(IGF-R1). 
3. Loss of negative regulators for PIP3, PTEN and 
INPP4B. 
4. Overexpression of AKT1, AKT2 and PDK1 [16].  
In breast cancer, the most common mutations of AKT 
which determine the overactivation of this signaling 
pathway are the loss of the negative PTEN regulator and 
the PIK3CA mutation [17]. These changes cause cell 
transformation, progression, and chair formation of the 
tumor mass. In 2004, PIK3A, which encodes the p110α 
catalytic subunit, was discovered to be the most common 
genetic mutation being considered a highly oncogenic 
gene [17]. Other mutations have been identified, for 
example, in the kinase domain H1047R, in the catalytic 
domain E542K and E545K [16]. She and co-workers 
identified a 25% reduction for PTEN in breast cancer; the 
same team of researchers observed in the case of triple 
negative breast cancer, characterized by a low survival 
rate, alteration with 30% of PTEN [18]. 
Endocrine resistance and PI3K/AKT 
Mutations in AKT signaling pathways may be 
responsible for resistance to hormonal treatment. 
Hyperactivation of receptors such as HER1, HER2, 
EGFR via AKT may contribute to the resistance of anti-
estrogen therapy [19].  
Several mechanisms have been described as 
responsible for endocrine resistance in breast cancer, such 
as disorders of the ER/PgR pathway components, 
modifications of signaling molecules involved in the cell 
cycle or survival, or activation of signaling pathways that 
ensure cell replication [20]. ER is composed of 2 
subunits, namely ERα and ERβ, being a nuclear receptor. 
Estrogen activation of ERα is responsible in many types 
of breast cancer for cell proliferation. In contrast, ERβ 
exhibits opposite effects of ERα, inhibiting the 
stimulatory effects of estradiol (E2) on cell proliferation. 
Alpha and beta receptors contain two transcriptional 
domains, namely AF1 and AF2, both of which have 
activation functions [21]. Binding of E2 to the ER leads to 
the activation of a number of processes that result in the 
translocation of chaperone proteins from the ERα 
receptor, receptor dimerization, phosphorylation and 
finally the binding of ER to DNA [22]. 
AF1 regulates gene transcription, even in cells that 
exhibit ERα deletion, being independent of ligand, AF2 
instead binds to coactivators or corepressors [23]. 
Activation of AF1 is mediated by crosslinks and crosstalk 
among the RAS/B-RAF, AKT and CDK2 (cyclin-
dependent kinase 2/7) pathways. This activation 
mechanism unfortunately leads to resistance observed in 
different endocrine therapies [24]. At the molecular level, 
estrone activity leads to activation of insulin-like growth 
factor (IGF), AKT, and MAPK signaling pathways. This 
activation will downregulate ER and PgR expression at 
the cell surface level [25].  
In the case of metastatic breast cancer, the AKT 
signaling pathway is most frequently altered, upregulation 
of this molecules promotes the transcriptional activity of 
ER that will contribute to anti-estrogen resistance, leading 
to tumor growth, motility, metabolism and survival [26]. 
Breast cancer biomarkers and therapy  
Currently, a number of AKT signaling pathway 
inhibitors are being studied, which generally focus on the 
simultaneous blocking of PI3K and mTOR. As already 
noted, there is a link between increased activity of PI3K 
and breast cancer tumorigenesis or drug resistance. Recent 
studies have revealed the importance of testing and using 
PI3K inhibitors in the tumor microenvironment [27]. 
Beneficial effects of PI3K inhibition have been 
observed in the treatment of leukemia, improving 
immunotherapy in solid cancer where it selectively blocks 
T cell-mediated immune tolerance [28]. For example, 
agent EL147 is a PI3K selective inhibitor that can block 
IPI3K class. This drug, which can be administered orally, 
cannot inhibit mTOR but a preclinical efficacy has been 
observed on PI3K and PTEN. Among the first drugs that 
were studied were those that were analogues of 
rapamycin, so mTOR inhibition may play a crucial role in 
the therapy of breast cancer. In a phase II randomized 
trial, patients diagnosed with breast tumors > 2cm ER+ 
received letrozole plus placebo for 16 weeks or letrozole 
and everolimus (rapamycin analog).  
The administration of everolimus had a better 
response rate to treatment. The use of mTOR inhibitors 
has beneficial effects in breast cancer therapy [29]. 
Breast cancer classification is currently performed 
according to histological evaluation, immunohistochemistry 
and genetic testing, and biomarker detection can be of real 
use in the most accurate diagnosis of this neoplastic disease. 
Increased expression of cytokeratin 5/6 and 17, laminin, and 
fatty acid binding protein was observed in basal-like tumors. 
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These biomarkers show a 15% increase in invasive cancers, 
being associated with breast cancer and BRCA 
mutations [30]. 
Depending on the molecular classification, Luminal A 
is a hormone receptor-positive breast cancer (estrogen 
receptor and / or progesterone receptor positive), HER2 
negative, and is associated with low levels of Ki-67 protein, 
which helps in rapid growth of cancer cells. Luminal A 
breast cancer has a lower degree, the proliferation rate is 
slow, and it has the best prognosis. Luminal B breast 
cancer is positive for hormone receptors (estrogen receptor 
and / or progesterone receptor positive) and HER2 positive 
or HER2 negative, associated with increased Ki-67 levels. 
The rate of proliferation of Luminal cancer B is faster than 
Luminal A breast cancer [30]. 
Negative/ basal triple breast cancer is the type of 
neoplasia without hormonal receptors (estrogen receptor 
and progesterone receptor negative) and HER2 negative. 
It unfortunately develops in women with BRCA1 gene 
mutations, among younger and African-American 
women. HER2-enriched breast cancer is hormone 
receptor negative (estrogen and progesterone) and HER2 
positive. These cancers have a faster proliferation rate 
than Luminal breast cancers and a poorer prognosis, 
although they may be successfully treated with therapies 
targeting the HER2 protein, such as Herceptin 
(trastuzumab), Perjeta (pertuzumab), Tykerb (lapatinib) 
and Nerlynx (neratinib) [30]. 
pS6K (S6 kinase) and pAKT are biomarkers of 
response to inhibitors for mTOR pathway (rapamycin 
analogues), tested on cell lines and tumors. Increased 
levels of pS6K are associated with a reserved survival 
prognosis [30]. Increased levels of phosphorylated 
proteins such as AKT, GSK3β, and TSC2 have been 
observed in various tumor cell lines [31]. 
INPP4B is a potential tumor suppressor biomarker that 
regulates AKT, so deletion of this phosphatase results in 
PTEN loss that will correlate with poor survival prognosis 
[31-33].  
An inhibitor of mTORC 1, everolimus was tested on 
breast cancer cell lines that had the PIKCA mutation 
where mTORC1 inhibition could be observed [31]. 
Ribosomal S6 kinases (RPS6KA2) and S4 (RSK4) 
and c-myc activation are mutations of the mitogen-
activated protein kinase signaling pathways (MAPK) that 
may be the key of resistance to AKT inhibitors. Positive 
effects have been reported for basal-like triple negative 
breast cancer where inhibitors for AKT and MAPK have 
been used [31]. 
Highlights 
✓ Mutations of the AKT signaling pathway components 
(especially PI3KCA and PTEN) have been observed 
in breast cancer patients, which are associated with 
resistance to hormonal treatment. 
✓ Mutations that occur at this signaling pathway cause 
AKT overactivation which will further lead to the 
activation of target molecules responsible for cell 
growth, survival and proliferation and protein 
synthesis of breast tumor cells. 
Conclusions 
AKT is an extremely complicated intracellular 
signaling pathway that has an important role in the 
pathogenesis of breast cancer. Mutations that occur at this 
signaling pathway cause AKT overactivation which will 
further lead to the activation of target molecules 
responsible for cell growth, survival, and proliferation and 
protein synthesis of breast tumor cells. 
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